Jazz Pharmaceuticals (JAZZ) - FREE Research Report Cozadd Bruce C who is Chairman and CEO at Jazz Pharmaceuticals sold 5,000 shares at $87.59 on Sept. 10, 2013. Following this transaction, the Chairman and CEO owned 629,647 shares meaning that the stake was reduced by 0.79% with the 5,000 share transaction. The shares most recently traded at $86.95, down $0.64, or 0.74% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:
4-Week # shares sold: 6,640
12-Week # shares sold: 29,208
24-Week # shares sold: 45,208
The average volume for Jazz Pharmaceuticals has been 809,000 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $5.0 billion and is part of the health care sector and drugs industry. Shares are up 64.3% year to date as of the close of trading on Tuesday. Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 18.5. Currently there are 12 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREETheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.